Tasosartan
From Self-sufficiency
| File:Tasosartan.png | |
| Systematic (IUPAC) name | |
|---|---|
|
2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one | |
| Identifiers | |
| ATC code | C09CA05 (WHO) |
| PubChem | CID 60919 |
| Chemical data | |
| Formula | C23H21N7O |
| Molar mass | 411.459 g/mol[[Script error: No such module "String".]] |
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
- ↑ Atkinson AJ; et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Tetrazoles
- Pyridopyrimidines
- Lactams
- Angiotensin II receptor antagonists
- Cardiovascular system drug stubs
- 2Fix
- CS1 maint: Explicit use of et al.
